New therapy targeting the hypoxic fraction of tumors needs to be designed as this population of cells is the most resistant to radio-and chemotherapies. Hypoxia-inducible factor (HIF) mediates transcriptional responses to hypoxia by binding to hypoxia-responsive elements (HRE) in target genes. We developed a hypoxia/HIF-dependent replicative adenovirus (HYPR-Ad) to target hypoxic cells. HYPR-Ad displays hypoxia-dependent E1A expression and conditional cytolysis of hypoxic but not normoxic cells. This work provides proof-of-principle evidence that an attenuated oncolytic adenovirus that selectively lyses cells under hypoxia can be generated. This therapeutic approach can be used to treat all solid tumors that develop hypoxia, regardless of their tissue origin or genetic alterations.
Introduction
The use of replication-competent gene therapy viruses, which have a cytolytic cycle, has emerged as a viable strategy to specifically kill tumor cells (oncolysis) and enhance adjuvant therapeutic gene transfer by viral spread throughout the tumor (Fulci and Chiocca, 2003) . Several of these viruses have exhibited low toxicity in clinical trials, supporting their use as viable cancer therapies (Markert et al., 2000; Kirn, 2001) . These viruses are targeted to tumor cells with specific genetic alterations or gene expression profiles and are therefore limited to tumors with the desired characteristics. Moreover, tumor cells lacking the desired attributes will have a selective advantage and survive. To complement these vectors, it would be desirable to have a set of vectors that are dependent upon microenvironmental constraints specific to tumor growth rather than cellintrinsic gene expression profiles or genetic alterations.
Hypoxia, a reduction in partial pressure of O 2 , is an integral component of the tumor microenvironment that develops in most solid tumors regardless of their origin, location, or genetic alterations. Oxygen electrode measurements in tumors found variable O 2 conditions (0-5%) with a median level of 1.3% (Brown, 2000) . Hypoxia is an abnormal physiological condition that arises from the rapid growth of the tumor relative to its vascular supply (Brown, 2000) . Moreover, hypoxia is a major factor in conferring resistance of cancer cells to radio-and chemo-therapies, can favor the selection of more malignant tumor clones, and is associated with a predisposition to metastasis (Graeber et al., 1996; Brown, 2000) . Therefore, it is important to develop novel therapeutic strategies that can specifically target hypoxic areas of tumors.
Low-oxygen conditions initiate a cascade of physiological responses resulting from the induction of genes involved in glycolysis, erythropoiesis, and angiogenesis (Semenza, 2000) . Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor that mediates responses to hypoxia by binding to a hypoxia-response element (HRE) present within target genes. There are three HIF a-subunits whose protein levels and activity are regulated by hypoxia while the b-subunit is constitutively expressed. The HIF/HRE system of gene regulation is active under hypoxia or as a result of genetic alterations during cell transformation, such as inactivation of the von Hippel-Lindau (pVHL) tumor suppressor which encodes a ubiquitin ligase involved in HIF degradation. Therefore, the HIF/HRE system can be utilized to specifically target therapeutic gene expression to tumors (Semenza, 2000) . Here, we examined the potential use of this system to regulate conditionally the replication of an adenovirus, thereby creating a novel type of oncolytic therapy vector, hypoxia/HIF-dependent replicative adenovirus (HYPR-Ad), that targets cells with activated HIF, such as hypoxic cells.
Construction of the first prototype of an HYPR-Ad (HYPR-Ad#1)
To construct an Ad that selectively replicates in hypoxic/HIF-active cells, we reintroduced a modified E1 gene region into a replication-deficient Ad (Figure 1a ). The expressions of E1A and E1B are essential for Ad replication; therefore, both gene regions were included in the construction of HYPR-Ad. We placed the E1A gene under the regulation the right arm of V6R 1 of a bidirectional hypoxia/HIF-responsive promoter derived from the VEGF gene. The left arm of the promoter was not used in this first prototype of HYPR-Ad (HYPR-Ad#1), although it is designed for the future incorporation of adjuvant therapy genes (see discussion). The E1B gene was restored with its endogenous regulatory elements.
Induction of hypoxia-dependent cytolysis by HYPR-Ad#1 in normal human fibroblast cells
The ability of HYPR-Ad#1 to conditionally induce cytolysis under hypoxia (1% O 2 ) and its potential cytotoxicity under normoxia (21% O 2 ) was examined using Hs68 normal human foreskin fibroblasts ( Figure 1b ). Normal cells were chosen so that HYPRAd#1 activity under normoxia could be assessed under physiological HIF protein levels and transcriptional activity. In tumor cells, HIF-1 levels and activity can be altered in response to genetic alterations that occur during cellular transformation (Semenza, 2000) . Viral dose-response studies were performed over a large range of multiplicity of infections (MOIs) to assess cytotoxicity at therapeutic and extreme viral doses, and because of the low transduction efficiency of Hs68 cells by Ads (27% infected with AdLacZ MOI 150, not shown). Two control viruses, AdLacZ (a replication-deficient Ad expressing LacZ and R lacking the E1 gene region) and dl309-Ad [a replication-competent Ad containing a wild-type E1 gene region (Bett, 1995) ], were used. The cells were infected at MOIs 1, 10, 100, 250, 500, and 1000 with HYPR-Ad#1, AdLacZ, dl309-Ad, or were left uninfected and then grown for 13 days under hypoxia or normoxia. After this time, uninfected and AdLacZinfected cells were 100% confluent under normoxia and hypoxia with no visual evidence of cell lysis/ detachment (cytopathic effect, CPE) even at an MOI of 1000, demonstrating that the hypoxic and viral infection conditions are not cytotoxic (Figure 1b) . Consistent with the low infection efficiency of these cells, low (10%) to no (0%) CPE was observed under normoxia or hypoxia following infection with dl309-Ad at MOI 1 or HYPR-Ad#1 at MOIs 1 and 10, respectively (not shown). Cells infected with dl309-Ad displayed 100% CPE at MOIs 10-1000 under both normoxia and hypoxia ( Figure 1b and not shown). In contrast, cells infected with HYPR-Ad#1 (MOIs 100-1000) and maintained under hypoxia underwent extensive CPE while those kept in normoxia displayed no obvious CPE ( Figure 1b and not shown). A few rounded-up cells (o1%) were observed under normoxia on day 13 with the highest doses of HYPR-Ad#1 (MOIs 250-1000), and will require further investigation to determine if these cells were infected with virus and if, subsequent to this, low levels of viral protein expression and/or replication occurred. Cell death was most likely the result of viral replicative oncolysis as the replication-defective AdLacZ-infected cells displayed no CPE. To generate an Ad that selectively replicates in hypoxic/HIF-active cells, a modified Ad type 5 (Ad5) E1 gene region was cloned into a replication-deficient Ad5 genome lacking the E1 and E3 genomic regions. The E1A gene was cloned downstream of V6R 1 a hypoxia/HIF-responsive promoter composed of six tandem copies of the HRE of the VEGF gene (6 Â VEGF-HRE) and a mini CMV promoter (Post and Van Meir, 2001 ). SV40 pA: SV40 poly A sequences; MCS: multiple cloning site that can be used for the insertion of an additional gene of interest. Methods: The Ad5 E1 genomic region from nucleotides 501 to 4105 was amplified by PCR with Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA, USA) using dl309-Ad template DNA (Bett, 1995) and primers Ad5-E1-F 5 0 ,-TCTTGAGTGCCAGCGAGTAG-3 0 and Ad5-E1-R 5 0 -AAAACCCCTAAATAAAGACAGC-3 0 and then cloned into the EcoRV site of pBI-V6R-HRE (Post and Van Meir, 2001) . DNA sequences spanning from the 5 0 end of the SV40 pA region to the 3 0 end of the E1B gene region within pBI-V6R-HRE-E1 were amplified by PCR using the SV40 pA 5 0 -TGGTCGAGCTGATACTTCCC-3 0 and Ad5-E1-R primers and then inserted into the EcoRV site of pShuttle (He et al., 1998) . Recombinant HYPR-Ad#1 was generated from pShuttle-V6R-HRE-E1 and pAdEasy-1 using the pAdEasy system (He et al., 1998) . (b) Hs68 cells (CRL-1635, American Type Culture Collection, Rockville, MD, USA) were monitored for CPE under normoxia (N, 21% O 2 ) and hypoxia (H, 1% O 2 ) following infection with AdLacZ, HYPR-Ad#1, dl309-Ad, or mock infected. Methods: Hypoxia was generated in a standard cell culture incubator by displacing O 2 with infusion of N 2 , which was supplied by an external high-pressure liquid nitrogen tank. A PROOX model 110 controller linked to an E-YYY oxygen sensor (Reming Bioinstruments Redfield, NY) regulated N 2 infusion. Purified, high titer viral stocks were obtained from the University of North Carolina Vector Core Facility (Chapel Hill, NC, USA). Multiplicity of infection (MOI) units represent focus forming units determined by immunofluorescence detection of Ad E2A protein in infected cells (UNC Vector Core Facility). Cells were infected under normoxia in DMEM 2.5% FCS for 2-3 h. Subsequently, virus was aspirated, DMEM 10% FCS was added, and the cells were incubated under normoxia or hypoxia. (c-e) Hs68 cells infected with HYPR-Ad#1 (MOI 150) and maintained under normoxia (N) or hypoxia (H) were examined for CPE (c) or for Ad5 E1A, E1B 21K, E1B 55K (d), and cellular HIF-1a (e) protein levels. M: mock infected; +: positive control for HIF-1a protein (Hela cells treated with CoCl 2 ) supplied with the anti-HIF-1a Ab. Methods: For HIF-1a, cells were lysed in SDS-DTT loading dye (50 mm Tris pH 6.8, 100 mm DTT, 2% SDS, 10% glycerol, 0.1% bromophenol blue) and then boiled for 5 min. The levels of actin were used to estimate protein amount in each lane for the HIF-1a blot as lysates at each time point did not contain equal amounts of cells. For Ad E1, cells were lysed in 50 mm Tris pH 7.5, 150 mm NaCl, 0.5% NP-40, 50 mm NaF, 1 mm Na 3 VO 4 , 1 mm DTT, 1 mm PMSF, 25 mg/ml leupeptin, 25 mg/ml aprotinin, and 150 mg/ml benzamidine and total protein concentrations of cleared supernatants were determined (Protein Assay Dye Reagent, BIO-RAD, Hercules, CA, USA). A measure of 25 mg (E1A and E1B 21K) or 50 mg (E1B 55K) of total protein or equal volumes of total cell lysate (HIF-1a) were analysed by Western blot analysis. Primary Abs were: mouse anti-HIF-1a (BD Biosciences, Bedford, MA, USA); goat anti-actin (Santa Cruz, Santa Cruz, CA, USA); 1 : 1 mixture of mouse anti-Ad E1A M73 and M-1 (L Gooding, Emory University, Atlanta, GA, USA); rat anti-Ad5 E1B 21K (Oncogene, Cambridge, MA, USA); or mouse anti-Ad5 E1B 55K (A Turnell, University of Birmingham, UK). Secondary Abs (Roche, Indianapolis, IN, USA) were goat anti-mouse IgG F(ab 0 ) 2 -POD, swine anti-goat IgG-POD, and goat anti-rat IgG-POD. Signal was detected using the supersignal west pico chemiluminescent substrate system (Pierce, Rockford, IL, USA). Quantification was done by densitometry using NIH Image 1.61 software A time course of HYPR-Ad#1-mediated cytolysis in normoxic and hypoxic Hs68 cells was then performed (Figure 1c ) with concomitant examination of viral E1 and cellular HIF-1a protein expression levels (see below). Consistent with the above findings, HYPRAd#1-infected (MOI 150) Hs68 fibroblasts did not undergo CPE under normoxia up to 13 days postinfection (Figure 1c) . In contrast, low levels of CPE (less than 5%) were observed under hypoxia through day 8. Between days 8 and 10, there was a large increase in the percentage of hypoxic cells undergoing cytolysis, from 5 to 50%, which then increased to 490% by day 13. These results demonstrate that HYPR-Ad#1 selectively induces CPE under hypoxia.
Hypoxia-dependent expression of E1A by HYPR-Ad#1-infected normal human fibroblast cells
The activity and specificity of the hypoxia/HIF-responsive promoter within HYPR-Ad#1 was evaluated by Western blot of E1A protein expression in infected Hs68 cells grown under normoxia versus hypoxia. E1A protein expression was not detectable in mock-or HYPR-Ad#1-infected Hs68 cells grown under normoxia (Figure 1d ). The level of E1A detected in cell lysates gradually increased between days 1 and 8 in hypoxic cells, reaching maximal levels on day 10 when a large increase in CPE was observed. This likely reflects increasing numbers of infected cells or E1A stabilization using the course of infection. By day 13, when 90% of the cells have undergone CPE, E1A levels strongly decreased in lysates of hypoxic cells. These results show that the hypoxia/HIF-dependent promoter maintains its proper regulation in the context of the Ad genome, and that we created a recombinant Ad able to conditionally express E1A under hypoxia.
We next confirmed expression of the E1B 21K and 55K proteins in infected Hs68 cells, as the corresponding E1B gene region was restored in HYPR-Ad#1 with its own promoter. We expected E1B expression under both normoxia and hypoxia, with a possible increase under hypoxia since the E1B promoter is known to be regulated by both E1A and other cellular factors (Parks et al., 1988 and references therein) . E1B 21K and 55K were both expressed in infected cells with increased levels under hypoxia (Figure 1d ). E1B gene activation by hypoxia-induced E1A likely explains increased E1B levels under hypoxia at day 6. Under normoxia, E1B 21K expression was higher than E1B 55K. This may be because of a lower sensitivity of the anti-E1B 55K antibody, since both proteins are alternative splice products of the E1B gene, or differential stability of these two proteins. These results confirm the functionality of the E1B gene region within HYPR-Ad#1.
To verify that cellular HIF-1a levels indeed correlate with E1A activation, we examined HIF-1a levels during HYPR-Ad#1 infection (Figure 1e ). Cells were lysed at days 1, 3, 6, and 10 postinfection when they were approximately 30, 70, 100, and 120% confluent, respectively, and equal volumes of lysates were analysed by Western blot. As expected, HIF-1a was not detectable under normoxia, which is consistent with the lack of cytolysis and E1A protein expression seen (Ishii et al., 1999) as described in the legend of Figure 1 . The cells were exposed to normoxia or hypoxia for 24 h (LN229, U251MG, D247MG) or 48 h (Daoy). HIF-1a protein levels were induced 1650-, 29-, 19-, and 26-fold in LN229, Daoy, U251MG, and D247MG cells, respectively, following exposure to hypoxia. (b) HIF (HIF-1a, 2a, 3a) transcriptional activity was measured under normoxia (N) versus hypoxia (H). The cells were transiently transfected under normoxia with pBI-GL V6R, a plasmid with a hypoxia/HIF-responsive luciferase gene (Post and Van Meir, 2001 ), or pBI TET, a negative control plasmid containing a tetracycline-inducible luciferase gene (not shown). Following an overnight recovery, the cells were exposed to normoxia or hypoxia for 48 h. Luciferase activity within the whole-cell extracts was measured and normalized to total protein (light units/mg protein) as described (Post and Van Meir, 2001 ). HIF activity was induced under hypoxia 51 (Po0.004)-, 69 (Po0.007)-, 88 (Po0.046)-, and 683 (Po0.022)-fold in LN229, Daoy, U251MG, and D247MG cells, respectively. Stars indicate a statistically significant (Student's t-test) hypoxic induction of reporter gene activity under these conditions in HYPR-Ad#1-infected Hs68 cells. In lysates of hypoxic cells, HIF-1a was clearly detectable at day 3 and amounts detected increased through day 10 with increased cell numbers in the extracts. It is at this time that HYPR-Ad#1-infected Hs68 cells are undergoing extensive cytolysis and express high levels of E1A. The cellular actin levels suggest that the difficulty in detecting HIF-1a on day 1 is most likely because of insufficient protein obtained from the cells at this time point since equal volumes of lysates were used for this analysis. These results are consistent with HYPR-Ad#1 E1A gene transcription being dependent upon hypoxia-induced HIF-1a protein expression.
Selection of human brain tumor cell lines containing a hypoxia-activated HIF pathway
To study hypoxia-dependent expression of E1A and cytolysis by HYPR-Ad#1 in tumor cells, we examined the preservation of a hypoxia-activated HIF pathway in a panel of histologically, genetically, and biologically diverse human brain tumor cell lines (Ishii et al., 1999) . HIF-1a can be expressed under normoxia in tumor cells (Zhong et al., 1999; Talks et al., 2000) because of its dysregulation by several oncogenes and tumor suppressor genes (Semenza, 2000) . We measured HIF-1a protein levels in LN229 and U251MG glioblastoma, D247MG gliosarcoma, and Daoy medulloblastoma cells under normoxia and hypoxia. Western blotting of total cell lysates showed that HIF-1a protein levels were dramatically induced in all four cell lines after exposure to hypoxia (Figure 2a ). To confirm that the increase in protein levels leads to an increase in biological activity, we independently measured the overall HIF (HIF-1a, 2a, and 3a) transcriptional activity in these cells using a transiently transfected HRE promoter-luciferase reporter gene plasmid (Post and Van Meir, 2001 ). HIF activity was induced in all cell lines after 48 h of hypoxia. HIF activity under normoxia was barely detectable and was similar to that obtained with a negative control plasmid (Figure 2b and not shown). These data show that these four brain tumor cell lines contain a functional hypoxia-activated HIF pathway and thus were selected for use in our subsequent studies aimed at determining the ability of HYPR-Ad#1 to kill cancer cells under hypoxia.
HYPR-Ad#1 induces cytolysis of diverse human brain tumor cell lines in a hypoxia-dependent manner
The ability of HYPR-Ad#1 to specifically induce cytolysis of hypoxic human tumor cells was examined in LN229, U251MG, D247MG, and Daoy cells (Figure  3a Figure 1 . LN229 cells were infected at MOI 25 and photographs were taken 7 days postinfection. U251MG cells were infected at MOI 1 and photographs were taken 6 days postinfection. D247MG cells were infected at MOI 10 (AdLacZ) or 1 (HYPR-Ad#1 and dl309-Ad) and photographs were taken 7 (dl309-Ad) and 20 (mock, AdLacZ, HYPR-Ad#1) days postinfection. Daoy cells were infected at MOI 5 (AdLacZ) or 1 (HYPR-Ad#1 and dl309-Ad) and photographs were taken 7 (dl309-Ad) and 12 (mock, AdLacZ, HYPR-Ad#1) days postinfection and HYPR-Ad#1). A low dose of HYPR-Ad#1 (MOI 1) induced 100% CPE in U251MG, D247MG, and Daoy cells in 6, 20, and 12 days, respectively, while LN229 cells required a slightly higher dose (MOI 25) to achieve 100% CPE in 7 days. Similar variability has been evidenced in other cell lines and with other conditionally replicating oncolytic viruses (Fueyo et al., 2000; Tsukuda et al., 2002) , and may reflect cell intrinsic differences in viral transduction, virus production, sensitivity to viral induced death, and/or degree of hypoxia-induced HIF protein levels and transcriptional activity. Despite these differences, the CPE response of all four cell lines to HYPR-Ad#1 was hypoxiadependent, with greater than 90% of cells infected with HYPR-Ad#1 showing CPE under hypoxia but not normoxia. As expected, cells infected with the dl309-Ad underwent 100% CPE under normoxia and hypoxia. Cell death was most likely the result of viral replicative oncolysis because the replication-defective AdLacZinfected cells and uninfected cells maintained under normoxia and hypoxia displayed no evidence of CPE. These data demonstrate that HYPR-Ad#1 is able to conditionally induce cytolysis under hypoxia in a diverse panel of tumor cell lines containing hypoxia-activated HIF protein.
E1 protein expression by HYPR-Ad#1 versus dl309 under normoxia versus hypoxia in LN229 glioma cells
To examine whether the hypoxia-dependent expression of E1A by HYPR-Ad#1 was as tightly regulated in tumor cells as seen in Hs68 normal fibroblasts, we evaluated E1A expression by Western blot of infected LN229 cells (Figure 4a ). E1A is first evident in cell lysates 12 h after infection and hypoxia exposure and continues through day 3. By day 6, when cells undergo maximal CPE, the levels of E1A under hypoxia are barely detectable. Very low, but detectable, E1A expressions is also seen at days 2, 3, and 6 under normoxia. Expressions of E1B 21K and 55K proteins were also detectable in HYPR-Ad#1-infected LN229 cells under hypoxia (Figure 4a ). Similar to the Hs68 cell data (Figure 1d ), E1B 21K protein was expressed at higher levels under hypoxia compared to normoxia. These data demonstrate that HYPR-Ad#1 can conditionally express the E1A viral replication protein in a hypoxiadependent manner in both normal and tumor cells.
We observed a distinct difference in the levels of E1A versus E1B proteins as HYPR-Ad#1-infected hypoxic cells approached 100% CPE. The levels of E1A decreased while E1B remained relatively constant (compare levels on day 10 versus day 13 for Hs68 cells in Figure 1d and day 3 versus day 6 for LN229 cells in Figure 4a ). To determine if this is unique to HYPRAd#1, E1A and E1B protein levels were examined in dl309-Ad-infected LN229 cells under the same conditions (Figure 4b and not shown). As expected, E1A and E1B expression by dl309-Ad was similar under normoxia and hypoxia throughout the time course. E1A, E1B 21K, and E1B 55K proteins were detectable 1 day postinfection. The levels of these proteins increased by day 2 and were maintained through day 3. On day 6, when the cells are undergoing 100% CPE, E1A expression dropped below detection whereas E1B expression remained strong (Figure 4b and not shown). During the CPE process, cells first detach from the dish and remain alive as floating cells for several days before undergoing cytolysis (Tollefson et al., 1999) . This difference in E1 protein expression is most likely because of continued expression of E1B in the infected floating cells (which were included in our analysis) prior to cytolysis. Further investigations are warranted to verify whether E1B expression might have a function during the final stages of viral replication and cell lysis. These data show that the pattern of E1A and E1B protein expression by HYPR-Ad#1 in late-stage infected hypoxic cells is similar to that of the wild-type dl309-Ad.
Discussion
We demonstrate that a hypoxic/HIF responsive promoter can be used to control the initiation of a virus replication, thereby creating a conditionally replicative oncolytic virus that can specifically lyse hypoxic tumor cells. Such a novel vector appears ideally suited to target the hypoxic regions of tumors that are most resistant to apoptosis, and conventional radio-and chemotherapies (Graeber et al., 1996; Brown, 2000) . It has been shown previously that HREs derived from different genes can direct reporter and therapeutic gene expression under hypoxic conditions in vitro and in vivo using mammalian expression plasmids (Dachs et al., 1997; Prentice et al., 1997; Ruan et al., 1999; Shibata et al., 2000) , and a variety of replication-deficient virus vector systems including retroviruses (Boast et al., 1999; Koshikawa et al., 2000; Modlich et al., 2000) , Ads (Griffiths et al., 2000) , and adeno-associated viruses (Ruan et al., 2001) . Moreover, the delivery of prodrug enzyme therapy using hypoxia/HIF-regulated promoters has been shown to result in tumor cell killing and a reduction in tumor growth (Griffiths et al., 2000; Koshikawa et al., 2000) . The development of HYPR-Ad#1 is a significant new development towards exploiting tumor hypoxia as a means to direct anticancer therapy. We generated HYPR-Ad#1, the first prototype of this novel line of hypoxia-targeting vectors, by placing the gene encoding the viral replication factor E1A under the control of a hypoxia/HIF-regulated promoter. We demonstrate that this virus conditionally expresses E1A under hypoxia in infected cells. The E1B gene region, which is under the regulation of its endogenous viral promoter in HYPRAd#1, also showed upregulation in response to hypoxia. This is most likely an indirect effect mediated by hypoxia-induced E1A since the E1B promoter is not known to be regulated by hypoxia. Early E1B gene expression has both E1A-dependent and -independent components (Dery et al., 1987; Glenn Ricciardi, 1988; Parks et al., 1988 and references therein) . The low-level expression of E1B proteins by HYPR-Ad#1 in the absence of detectable E1A under normoxia most likely reflects E1A-independent basal activity of the E1B promoter. Most importantly, infection of normal fibroblasts and a panel of histologically (glioblastoma, gliosarcoma, and medulloblastoma), genetically (status of p53, p16, p14 ARF , and PTEN tumor suppressor genes), and biologically (in vitro and in vivo growth characteristics) diverse brain tumor cells led to selective cytolysis under hypoxic conditions (1% O 2 ).
We further anticipate that HYPR-Ad#1 should be particularly effective against tumors with an active HIF under normoxia (Semenza, 2000) . For example, the majority of sporadic CNS hemangioblastomas and sporadic clear cell carcinomas of the kidney contain a loss of pVHL tumor suppressor protein function. pVHL binds to HIF a-subunits under normoxia and targets these proteins for ubiquitin-mediated proteolysis. Moreover, HIF-1a is overexpressed in numerous other types of primary and metastatic human tumors (Zhong et al., 1999; Talks et al., 2000) consistent with its regulation by several oncogenes and tumor suppressor genes that are altered during cellular transformation (Semenza, 2000) .
The therapeutic efficacy of HYPR-Ad vectors can be potentially augmented, beyond direct cell killing through the lytic cycle of the virus, by their ability to deliver adjuvant therapeutic genes. HYPR-Ad design is modular with a bidirectional hypoxia/HIF-responsive promoter (Post and Van Meir, 2001 ), which can be used to conditionally coregulate the expression of E1A and a therapeutic gene of up to 2844 bp in length (Figure 1) . In principle, these adjuvant therapy genes could be any protein with tumor inhibitory activity such as cell cycle inhibitors, growth and tumor suppressors, inhibitors of cell anchoring, stimulators of the immune system such as cytokines, or inhibitors of angiogenesis. Expression of the latter in the tumor microenvironment might generate new areas of hypoxia following vascular collapse and lead to additional cycles of viral oncolysis. The ability to arm HYPR-Ad with adjuvant therapy genes is important as the antitumor effects of conditionally replicating Ad (CRAds) as single agents in clinical trials have been modest (Kruyt and Curiel, 2002) .
The use of HYPR-Ad's as an antitumor therapy has many potential advantages. First, this strategy is expected to be applicable to treat all cancer types that become hypoxic and/or demonstrate HIF activation regardless of their tissue of origin or genetic alterations. Second, it is anticipated that HYPR-Ad's will kill hypoxic endothelial cells within the tumor microenvironment which might amplify tumor cell death because of, the tumor's dependence on a vascular supply. Third, tumors should be less sensitive to developing resistance to HYPR-Ad's therapy by genetic selection. It is unlikely that a tumor cell population with suppressed activation of all HIF subunits would survive or evolve as these proteins activate gene programs essential for cell metabolic adaptation and survival under hypoxia (Semenza, 2000) . While HYPR-Ad's entry into tumor cells is expected to be dependent upon cell surface coxsackie-adenovirus receptor (CAR) expression and integrin isotype, modification of viral fiber protein can be achieved to bypass CAR dependency (Kruyt and Curiel, 2002) . Fourth, since hypoxia is an important factor in the resistance of tumors to radio-and chemotherapies, cotreatment with HYPR-Ad should augment these conventional therapies. Fifth, the design of HYPR-Ad's as bidirectional vectors opens the opportunity for arming the virus with additional anticancer genes. Our laboratory is actively pursuing these hypotheses. While HYPR-Ad's have many potential advantages, it will be important to have a clear understanding of all the factors that can modulate HIF protein levels and transcriptional activity. While upregulation of HIF in tumor cells by hypoxiaindependent mechanisms is expected to augment HYPR-Ad efficacy, increased HIF under certain physiological conditions in normal tissues could allow viral replication at unwanted sites. HIF is modulated by several growth factors in culture, although this effect is cell line and culture condition specific (Semenza, 2000) . Precise definition of these situations will determine optimal risk/benefit ratio and whether local or systemic delivery will be most appropriate. We show here that HYPR-Ad#1 does not lyse human fibroblasts under normal culture conditions.
In conclusion, we have developed a novel Ad-based oncolytic therapy using a tumor-restrictive hypoxia/HIF promoter to drive viral E1A gene expression and provide proof-of-principle data demonstrating that this virus selectively induces cytolysis under hypoxia in infected cells that contain a functional hypoxia/HIF pathway. A similar strategy could be applied for the conditional replication of other oncolytic viruses such as herpes simplex virus (HSV). These novel features of HYPR-Ad offer several advantages over all known cancer therapy vectors and suggest that a new generation of vectors exploiting the physiological state of the cells in response to natural (pH, redox, or metabolic status) or artificial (radiation, UV, or IR light) microenvironmental conditions might be exploited for cancer therapy.
Abbreviations HIF-1, hypoxia-inducible factor-1; HRE, hypoxia-responsive elements; HYPR-Ad#1, hypoxia/HIF-dependent replicative adenovirus; CRAd, conditionally replicating Ad; CPE, cytopathic effect; MOI, multiplicity of infection.
